DPX Delivery Platform Could Improve Care For Many Rare Cancers
source: pixabay.com

DPX Delivery Platform Could Improve Care For Many Rare Cancers

IMV Inc. recently presented two posters at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics showcasing their DPX delivery platform's immunotherapeutic capabilities. IMV Inc. IMV Inc. is…

Continue Reading DPX Delivery Platform Could Improve Care For Many Rare Cancers

Durvalumab Hopes to be Treatment Option for Malignant Pleural Mesothelioma

According to a recent article from OncologyLive, investigators are looking at durvalumab to aid in the treatment of adults with malignant pleural mesothelioma in the Phase 3 DREAM3R Trial. Malignant…

Continue Reading Durvalumab Hopes to be Treatment Option for Malignant Pleural Mesothelioma

First Patient Enrolled in NUZYRA Trial for NTM Lung Disease

On October 18, 2021, biopharmaceutical company Paratek Pharmaceuticals, Inc. ("Paratek") shared via news release that the first patient had enrolled in a Phase 2b clinical trial. Within the trial, researchers…

Continue Reading First Patient Enrolled in NUZYRA Trial for NTM Lung Disease